The combination of memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist, with an acetylcholinesterase inhibitor (AChEI) is the current standard of care in Alzheimer's disease (AD). This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.